X4 Pharmaceuticals Toekomstige groei
Future criteriumcontroles 3/6
X4 Pharmaceuticals's earnings are forecast to decline at 8% per annum while its annual revenue is expected to grow at 54.8% per year. EPS is expected to grow by 4.8% per annum. Return on equity is forecast to be 46.3% in 3 years.
Belangrijke informatie
-8.0%
Groei van de winst
4.8%
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 54.8% |
Toekomstig rendement op eigen vermogen | 46.3% |
Dekking van analisten | Good |
Laatst bijgewerkt | 13 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 101 | -77 | N/A | N/A | 6 |
12/31/2025 | 44 | -111 | N/A | N/A | 7 |
12/31/2024 | 6 | -43 | N/A | N/A | 7 |
6/30/2024 | 1 | 18 | -120 | -112 | N/A |
3/31/2024 | N/A | -129 | -104 | -104 | N/A |
12/31/2023 | N/A | -101 | -97 | -97 | N/A |
9/30/2023 | N/A | -111 | -88 | -88 | N/A |
6/30/2023 | N/A | -131 | -86 | -86 | N/A |
3/31/2023 | N/A | -96 | -83 | -83 | N/A |
12/31/2022 | N/A | -96 | -77 | -77 | N/A |
9/30/2022 | N/A | -103 | -77 | -77 | N/A |
6/30/2022 | N/A | -102 | -72 | -72 | N/A |
3/31/2022 | N/A | -100 | -73 | -73 | N/A |
12/31/2021 | N/A | -103 | -72 | -71 | N/A |
9/30/2021 | N/A | -85 | -70 | -69 | N/A |
6/30/2021 | N/A | -82 | -71 | -69 | N/A |
3/31/2021 | N/A | -78 | -63 | -62 | N/A |
12/31/2020 | 3 | -62 | -60 | -59 | N/A |
9/30/2020 | 3 | -55 | -52 | -51 | N/A |
6/30/2020 | 3 | -55 | -50 | -49 | N/A |
3/31/2020 | 3 | -53 | -53 | -52 | N/A |
12/31/2019 | N/A | -53 | -48 | -48 | N/A |
9/30/2019 | N/A | -55 | -46 | -46 | N/A |
6/30/2019 | N/A | -46 | -40 | -39 | N/A |
3/31/2019 | N/A | -40 | -31 | -31 | N/A |
12/31/2018 | N/A | -36 | -25 | -25 | N/A |
9/30/2018 | N/A | -31 | -23 | -23 | N/A |
12/31/2017 | N/A | -25 | N/A | -21 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: XFOR's earnings are forecast to decline over the next 3 years (-8% per year).
Winst versus markt: XFOR's earnings are forecast to decline over the next 3 years (-8% per year).
Hoge groeiwinsten: XFOR's earnings are forecast to decline over the next 3 years.
Omzet versus markt: XFOR's revenue (54.8% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: XFOR's revenue (54.8% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: XFOR's Return on Equity is forecast to be very high in 3 years time (46.3%).